In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints

被引:7
作者
Lascols, C. [1 ]
Legrand, P. [1 ]
Merens, A. [2 ]
Leclercq, R. [3 ]
Muller-Serieys, C. [4 ]
Drugeon, H. B. [5 ]
Kitzis, M. D. [6 ]
Reverdy, M. E. [7 ]
Roussel-Delvallez, M. [8 ]
Moubareck, C. [9 ]
Bremont, S. [9 ]
Miara, A. [10 ]
Gjoklaj, M. [10 ]
Soussy, C. -J. [1 ]
机构
[1] Univ Paris 12, CHU Henri Mondor, AP HP, Serv Bacteriol Virol Hyg, F-94010 Creteil, France
[2] Hop Instruct Armees Begin, Med Biol Lab, St Mande, France
[3] CHU Cote Nacre, Microbiol Lab, Caen, France
[4] CHU Bichat, AP HP, Lab Bacteriol & Virol, Paris, France
[5] CHU Guillaume & Rene Laennec, Bacteriol Lab, Nantes, France
[6] Hop St Joseph, AP HP, Serv Microbiol Med, F-75674 Paris, France
[7] CHU Edouard Herriot, Cent Microbiol Lab, Lyon, France
[8] CHRU Calmette, Lab Bacteriol & Virol, Lille, France
[9] Inst Pasteur, Ctr Natl Reference Resistance Antibiot CRAB, Unite Agents Antibacteriens, Paris, France
[10] Janssen Cilag, Issy Les Moulineaux, France
关键词
Ceftobiprole; New cephalosporin; In vitro activity; Breakpoints; BROAD-SPECTRUM CEPHALOSPORIN; METHICILLIN-RESISTANT; STAPHYLOCOCCUS-AUREUS; BAL9141; ENDOCARDITIS;
D O I
10.1016/j.ijantimicag.2010.11.035
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The aims of this study were to determine the in vitro activity profile of ceftobiprole, a pyrrolidinone cephalosporin, against a large number of bacterial pathogens and to propose zone diameter breakpoints for clinical categorisation according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) minimum inhibitory concentration (MIC) breakpoints. MICs of ceftobiprole were determined by broth microdilution against 1548 clinical isolates collected in eight French hospitals. Disk diffusion testing was performed using 30 mu g disks according to the method of the Comite de l'Antibiogramme de la Societe Francaise de Microbiologie (CA-SFM). The in vitro activity of ceftobiprole, expressed by MIC(50/90) (MICs for 50% and 90% of the organisms, respectively) (mg/L), was as follows: meticillin-susceptible Staphylococcus aureus, 0.25/0.5; meticillin-resistant S. aureus (MRSA), 1/2; meticillin-susceptible coagulase-negative staphylococci (CoNS), 0.12/0.5; meticillin-resistant CoNS, 1/2; penicillin-susceptible Streptococcus pneumoniae, <= 0.008/0.03; penicillin-resistant S. pneumoniae, 0.12/0.5; viridans group streptococci, 0.03/0.12; beta-haemolytic streptococci, <= 0.008/0.016;Enterococcus faecalis, 0.25/1; Enterococcus faecium, 64/128; Enterobacteriaceae, 0.06/32; Pseudomonas aeruginosa, 4/16; Acinetobacter baumannii, 0.5/64; Haemophilus influenzae, 0.03/0.12; and Moraxella catarrhalis, 0.25/0.5. According to the regression curve, zone diameter breakpoints could be 28, 26, 24 and 22 mm for MICs of 0.5, 1, 2 and 4 mg/L respectively. In conclusion, this study confirms the potent in vitro activity of ceftobiprole against many Gram-positive bacteria, including MRSA but not E. faecium, whilst maintaining a Gram-negative spectrum similar to the advanced-generation cephalosporins such as cefepime. Thus ceftobiprole appears to be well suited for the empirical treatment of a variety of healthcare-associated infections. (C) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:235 / 239
页数:5
相关论文
共 14 条
[1]  
[Anonymous], CLIN BREAKP
[2]  
[Anonymous], 2012, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Approved Standard
[3]   Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin [J].
Bogdanovich, T ;
Ednie, LM ;
Shapiro, S ;
Appelbaum, PC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (10) :4210-4219
[4]   Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus [J].
Chambers, HF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :884-888
[5]   BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis [J].
Entenza, JM ;
Hohl, P ;
Heinze-Krauss, I ;
Glauser, MP ;
Moreillon, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :171-177
[6]   In Vivo Activity of Ceftobiprole in Murine Skin Infections Due to Staphylococcus aureus and Pseudomonas aeruginosa [J].
Fernandez, Jeffrey ;
Hilliard, Jamese J. ;
Abbanat, Darren ;
Zhang, Wenyan ;
Melton, John L. ;
Santoro, Colleen M. ;
Flamm, Robert K. ;
Bush, Karen .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) :116-125
[7]   In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci [J].
Hebeisen, P ;
Heinze-Krauss, I ;
Angehrn, P ;
Hohl, P ;
Page, MGP ;
Then, RL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :825-836
[8]   In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria [J].
Issa, NC ;
Rouse, MS ;
Piper, KE ;
Wilson, WR ;
Steckelberg, JM ;
Patel, R .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (01) :73-75
[9]   In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci [J].
Jones, RN ;
Deshpande, LM ;
Mutnick, AH ;
Biedenbach, DJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (06) :915-932
[10]  
KAHLMETER G, 2010, EUR C CLIN MICR INF